Skip to main content

Advertisement

SpringerLink
Log in

Expression of Galectin-3 in Pancreatic Ductal Adenocarcinoma

  • Research
  • Published:
Pathology & Oncology Research

Abstract

Galectin-3 influences neoangiogenesis, tumor cell adhesion, and tumor-immune-escape mechanisms. Hence, the expression of galectin-3 in pancreatic ductal adenocarcinoma (PDAC) was evaluated. Galectin-3 expression in PDAC cell lines was proven by the presence of intracellular protein and by release into the supernatant. Furthermore, galectin-3 was found in the majority of human tissue samples. Serum concentrations of galectin-3 in PDAC patients did not differ significantly from healthy donors and did not correlate with established tumor markers. In conclusion, galectin-3 is expressed in PDAC tissues suggesting a role in tumor development; however, no relationship between expression and clinical findings could be established.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Abbreviations

CEA:

Carcinoembryonic antigen

CPB:

Cyclophylin B

H&E:

Haematoxylin and eosin

IQR:

Interquartile range

PBS:

Phosphate-buffered saline

PDAC:

Pancreatic ductal adenocarcinoma

TMA:

Tissue microarray

References

  1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60:277–300

  2. Li D, Xie K, Wolff R, Abbruzzese JL (2004) Pancreatic cancer. Lancet 363:1049–1057

    Article  PubMed  CAS  Google Scholar 

  3. Warshaw AL, Fernandez del Castillo C (1992) Pancreatic carcinoma. N Engl J Med 326:455–465

    Article  PubMed  CAS  Google Scholar 

  4. Thijssen VL, Postel R, Brandwijk RJ, Dings RP, Nesmelova I, Satijn S, Verhofstad N, Nakabeppu Y, Baum LG, Bakkers J, Mayo KH, Poirier F, Griffioen AW (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103:15975–15980

    Article  PubMed  CAS  Google Scholar 

  5. Goetz JG, Joshi B, Lajoie P, Strugnell SS, Scudamore T, Kojic LD, Nabi IR (2008) Concerted regulation of focal adhesion dynamics by galectin-3 and tyrosine-phosphorylated caveolin-1. J Cell Biol 180:1261–1275

    PubMed  CAS  Google Scholar 

  6. Hittelet A, Legendre H, Nagy N, Bronckart Y, Pector JC, Salmon I, Yeaton P, Gabius HJ, Kiss R, Camby I (2003) Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 103:370–379

    Article  PubMed  CAS  Google Scholar 

  7. Rubinstein N, Alvarez M, Zwirner NW, Toscano MA, Ilarregui JM, Bravo A, Mordoh J, Fainboim L, Podhajcer OL, Rabinovich GA (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; A potential mechanism of tumor-immune privilege. Cancer Cell 5:241–251

    Article  PubMed  CAS  Google Scholar 

  8. Canesin G, Gonzalez-Peramato P, Palou J, Urrutia M, Cordon-Cardo C, Sanchez-Carbayo M (2010) Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol 31:277–285

    Article  PubMed  CAS  Google Scholar 

  9. Sakaki M, Oka N, Nakanishi R, Yamaguchi K, Fukumori T, Kanayama HO (2008) Serum level of galectin-3 in human bladder cancer. J Med Invest 55:127–132

    Article  PubMed  Google Scholar 

  10. Yang RY, Rabinovich GA, Liu FT (2008) Galectins: structure, function and therapeutic potential. Expert Rev Mol Med 10:e17

    Article  PubMed  Google Scholar 

  11. Dumic J, Dabelic S, Flogel M (2006) Galectin-3: an open-ended story. Biochim Biophys Acta 1760:616–635

    Article  PubMed  CAS  Google Scholar 

  12. Liu FT, Hsu DK (2007) The role of galectin-3 in promotion of the inflammatory response. Drug News Perspect 20:455–460

    PubMed  CAS  Google Scholar 

  13. de Boer RA, Yu L, van Veldhuisen DJ (2010) Galectin-3 in cardiac remodeling and heart failure. Curr Heart Fail Rep 7:1–8

    Article  PubMed  Google Scholar 

  14. de Boer RA, Lok DJ, Jaarsma T, van der MP, Voors AA, Hillege HL, van Veldhuisen DJ (2011) Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann Med 43:60–68

    Article  PubMed  Google Scholar 

  15. Lok DJ, van der MP, de la Porte PW, Lipsic E, Van WJ, Hillege HL, van Veldhuisen DJ (2010) Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study. Clin Res Cardiol 99:323–328

    Article  PubMed  CAS  Google Scholar 

  16. Cvejic D, Savin S, Petrovic I, Selemetjev S, Paunovic I, Tatic S, Havelka M (2005) Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma. Exp Oncol 27:210–214

    PubMed  CAS  Google Scholar 

  17. Zaia PL, Oshima CT, de Oliveira LF, ndrade Scherholz PL, Manoukian FN (2010) Immunoexpression of galectin-3 in colorectal cancer and its relationship with survival. J Gastrointest Cancer.

  18. Choi JY, Cho SI, Do NY, Kang CY, Lim SC (2010) Clinical significance of the expression of galectin-3 and Pim-1 in laryngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg 39:28–34

    PubMed  Google Scholar 

  19. Sakaki M, Fukumori T, Fukawa T, Elsamman E, Shiirevnyamba A, Nakatsuji H, Kanayama HO (2010) Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J Med Invest 57:152–157

    Article  PubMed  Google Scholar 

  20. Vereecken P, Awada A, Suciu S, Castro G, Morandini R, Litynska A, Lienard D, Ezzedine K, Ghanem G, Heenen M (2009) Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients. Melanoma Res 19:316–320

    Article  PubMed  CAS  Google Scholar 

  21. Wang L, Friess H, Zhu Z, Frigeri L, Zimmermann A, Korc M, Berberat PO, Büchler MW (2000) Galectin-1 and galectin-3 in chronic pancreatitis. Lab Invest 80:1233–1241

    Article  PubMed  CAS  Google Scholar 

  22. Geers C, Moulin P, Gigot JF, Weynand B, Deprez P, Rahier J, Sempoux C (2006) Solid and pseudopapillary tumor of the pancreas–review and new insights into pathogenesis. Am J Surg Pathol 30:1243–1249

    Article  PubMed  Google Scholar 

  23. Berberat PO, Friess H, Wang L, Zhu Z, Bley T, Frigeri L, Zimmermann A, Büchler MW (2001) Comparative analysis of galectins in primary tumors and tumor metastasis in human pancreatic cancer. J Histochem Cytochem 49:539–549

    Article  PubMed  CAS  Google Scholar 

  24. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, Tanaka K, Sekihara H, Hirohashi S (2002) Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 8:2570–2575

    PubMed  CAS  Google Scholar 

  25. Hamilton SR, Aaltonen LA (2000) World Health Organisation classification of tumours. Pathology and genetics of tumours of the digestive system. IARC, Lyon

  26. Sobin LH, Gospodarowicz MK, Wittekind C (2009) TNM classification of malignant tumours. Wiley-Blackwell, Oxford

  27. Bergmann F, Breinig M, Hopfner M, Rieker RJ, Fischer L, Kohler C, Esposito I, Kleeff J, Herpel E, Ehemann V, Friess H, Schirmacher P, Kern MA (2009) Expression pattern and functional relevance of epidermal growth factor receptor and cyclooxygenase-2: novel chemotherapeutic targets in pancreatic endocrine tumors? Am J Gastroenterol 104:171–181

    Article  PubMed  CAS  Google Scholar 

  28. Ceyhan GO, Bergmann F, Kadihasanoglu M, Erkan M, Park W, Hinz U, Giese T, Müller MW, Büchler MW, Giese NA, Friess H (2007) The neurotrophic factor artemin influences the extent of neural damage and growth in chronic pancreatitis. Gut 56:534–544

    Article  PubMed  CAS  Google Scholar 

  29. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA, Friess H (2005) Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene 24:4421–4432

    Article  PubMed  CAS  Google Scholar 

  30. Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, Lazar AJ, Shen SS, Zhang PS, Reed JA, Gershenwald JE, Raz A, Bar-Eli M (2006) Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res 12:6709–6715

    Article  PubMed  CAS  Google Scholar 

  31. Xu XC, el-Naggar AK, Lotan R (1995) Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. Am J Pathol 147:815–822

    PubMed  CAS  Google Scholar 

  32. Saussez S, Glinoer D, Chantrain G, Pattou F, Carnaille B, Andre S, Gabius HJ, Laurent G (2008) Serum galectin-1 and galectin-3 levels in benign and malignant nodular thyroid disease. Thyroid 18:705–712

    Article  PubMed  CAS  Google Scholar 

  33. Koopmann J, Thuluvath PJ, Zahurak ML, Kristiansen TZ, Pandey A, Schulick R, Argani P, Hidalgo M, Iacobelli S, Goggins M, Maitra A (2004) Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. Cancer 101:1609–1615

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We thank Birgit Prior, Institute of Immunology, University of Heidelberg and Sarah Messnard, Institute of Pathology, University of Heidelberg for excellent technical support. We also thank Thomas Giese, Institute of Immunology, University of Heidelberg for performing quantitative RT-PCR.

Part of this work has been financially supported by a grant of the “Heidelberg Surgery Foundation” to G.M.H. and M.N.W. All authors declare that they have no conflict of interest to disclose.

Author information

Author notes

  1. Frank Günther

    Present address: Institute of Hygiene and Microbiology, University of Würzburg, 97080, Würzburg, Germany

  2. Moritz N. Wente

    Present address: Department of Medical Scientific Affairs, Aesculap AG, Am Aesculap-Platz, 78532, Tuttlingen, Germany

Authors and Affiliations

  1. Institute of Pathology, University of Heidelberg, 69120, Heidelberg, Germany

    Matthias M. Gaida, Sylvia T. Bach, Darjus F. Tschaharganeh & Frank Bergmann

  2. Institute of Immunology, University of Heidelberg, 69120, Heidelberg, Germany

    Sylvia T. Bach, Frank Günther, Billur Baseras & Gertrud M. Hänsch

  3. Department of Surgery, University of Heidelberg, 69120, Heidelberg, Germany

    Thilo Welsch, Klaus Felix & Moritz N. Wente

Authors
  1. Matthias M. Gaida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sylvia T. Bach
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Frank Günther
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Billur Baseras
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Darjus F. Tschaharganeh
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Thilo Welsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Klaus Felix
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Frank Bergmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Gertrud M. Hänsch
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Moritz N. Wente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Moritz N. Wente.

Electronic Supplementary Materials

Below is the link to the electronic supplementary material.

Supplementary Table 1

(DOCX 20.4 kb)

Supplementary Table 2

(DOCX 20.6 kb)

Supplementary Table 3

(DOCX 19.7 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gaida, M.M., Bach, S.T., Günther, F. et al. Expression of Galectin-3 in Pancreatic Ductal Adenocarcinoma. Pathol. Oncol. Res. 18, 299–307 (2012). https://doi.org/10.1007/s12253-011-9444-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12253-011-9444-1

Keywords

Search

Navigation